# PBH — Prestige Consumer Healthcare Inc. · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** PBH  
**Sources:** 5  
**Published:** 2026-08-06  
**Canonical:** https://app.k3vl4r.com/research/deep-research-pbh-prestige-consumer-healthcare-inc-catalysts-narrative-1642

---

## Prestige Consumer Healthcare Inc. (PBH) — Research Snapshot as of 2026-11-10

**Company profile:** PBH develops, manufactures, markets, distributes, and sells branded over-the-counter (OTC) health and personal care products, with key brands including Clear Eyes (redness relief) and Dramamine (motion sickness) [[1]](https://finance.yahoo.com/research/reports/MS_0P000004FZ_AnalystReport_1793929718000). It is described as one of the largest pure-play OTC healthcare providers [[1]](https://finance.yahoo.com/research/reports/MS_0P000004FZ_AnalystReport_1793929718000). On the most recent close (9 Nov 2026), the stock traded in a tight cluster across sources at roughly $43–$44 — reported as $44 by Ticker Nerd [[2]](https://tickernerd.com/stock/pbh-forecast/), $42.98 by 24/7 Wall St. [[3]](https://247wallst.com/companies/pbh/price-prediction/), and $43.67 by StockAnalysis [[4]](https://stockanalysis.com/stocks/pbh/forecast/).

## Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-pbh-prestige-consumer-healthcare-inc-catalysts-narrative-1642 (free to sign up)._
